FT011

• CAT Number: I000070
• CAS Number: 1001288-58-9
• Molecular Formula: C20H17NO5
• Molecular Weight: 351.35
• Purity: ≥95%
• Target: MMP
• Solubility: DMSO ≥ 29 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid
• InChI: InChI=1S/C20H17NO5/c1-3-12-26-17-10-8-14(13-18(17)25-2)9-11-19(22)21-16-7-5-4-6-15(16)20(23)24/h1,4-11,13H,12H2,2H3,(H,21,22)(H,23,24)/b11-9+
• InChIKey: UIWZIDIJCUEOMT-PKNBQFBNSA-N
• SMILES: COC1=C(C=CC(=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OCC#C

FT011（Cat No.:I000070） is a novel compound with anti-fibrotic and anti-inflammatory properties. It functions by inhibiting the accumulation of glycogen, a form of stored glucose, within cells. This effect is achieved by reducing the translation of glycogen in mRNA, a key molecule involved in glycogen synthesis. By preventing excessive glycogen accumulation, FT011 may help mitigate fibrosis and inflammation, offering potential therapeutic benefits in diseases characterized by aberrant glycogen metabolism, such as certain liver and muscle disorders.

Reference

[1]. Lau X Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Diabetologia. 2013 Mar;56(3):675-9.

[2]. Deliyanti D et al. FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS One. 2015 Jul 29;10(7):e0134392.

[3]. Gilbert RE et al. A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat.
PLoS One. 2012;7(10)